Alpine Immune Sciences (NASDAQ:ALPN) reported its Q3 2020 results, highlighting a revenue increase to $1.9 million, up from $0.3 million in Q3 2019. The company successfully raised $60 million in a private placement, enhancing its cash position to $141.3 million. Key developments include preparations for a Phase 2 study of ALPN-101 for systemic lupus erythematosus and ongoing enrollment in a Phase 1 study for ALPN-202. Despite a net loss of $6.1 million in Q3 2020, sufficient funds are projected to support operations into 2024.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will announce its third quarter 2020 financial results on November 12, 2020, after market closure. The company will also host a conference call and live webcast at 4:30 p.m. ET to discuss these results along with a corporate update. For those wishing to join the call, the domestic phone number is (800) 816-3005 and the international number is (857) 770-0069. A replay will be available on the company’s website for 90 days following the live event.